Journal article
The economics of adjunctive therapies in coronary angioplasty: Drugs, devices or both?
Abstract
Oh and colleagues in Can J Clin Pharmacol Vol 11(2) Fall 2004:e202-e211; September 1, 2004 have provided a cost-effectiveness analysis (CEA) demonstrating that abciximab is more cost-effective than other commonly used therapies (for example, coronary artery stenting) and that it should be more universally used in PCI patients. The incremental cost-effectiveness ratio of $2,832 to $7,173 per life year gained with abciximab demonstrates greater …
Authors
Raco DL
Journal
Canadian Journal of Clinical Pharmacology, Vol. 11, No. 2, pp. e212–e213
Publication Date
January 1, 2004
ISSN
1198-581X